International Medication Safety Self Assessment for Oncology Practice
Philip E. Johnson,C. Chambers,A. Vaida,Ann D Shastay,J. Greenall
DOI: https://doi.org/10.1177/1078155211426761
2011-11-30
Journal of Oncology Pharmacy Practice
Abstract:A comprehensive survey of compliance to oncology medication safe practice standards was conducted in 2008 with results published (J. Oncology Pharm Practice 2008, 14: 169–180). Responses from 377 participants representing 34 countries demonstrated a wide variance in adherence to established standards and best practices (22.3– 98.3%). Since then, new standards have been published by several organizations, and new ‘best practices’ have been promoted through publications and presentations. There are currently multiple standards, and it is clear from medication error reports that many important standards are not fully understood and compliance is not optimal. The Institute for Safe Medication Practices (ISMP), ISMP Canada, and the International Society of Oncology Pharmacy Practitioners (ISOPP) will be launching the 2012 ISMP International Medication Safety Self Assessment for Oncology, a self-assessment tool designed to help hospitals and ambulatory cancer centers throughout the world evaluate oncology medication safety. This tool will establish an international baseline for safe medication practices related to oncology practice and will identify areas for improvement. A multidisciplinary team of 29 international experts evaluated published world standards which resulted in a consensus opinion on current best practices. This was the basis for the development of the oncology self assessment tool. The assessment items are divided into the key elements (domains) that most significantly influence a safe medication use process. The key elements include: (1) Patient information, (2) Drug information, (3) Communication of drug orders and other drug information, (4) Drug labeling, packaging and nomenclature, (5) Drug standardization, storage and distribution, (6) Medication device acquisition, use and monitoring, (7) Environmental factors, workflow and staffing patterns, (8) Staff competency and education, (9) Patient education, and (10) Quality processes and risk management. As with ISMP’s previous self-assessments, healthcare organizations will be asked to convene multidisciplinary teams to complete the self assessment tool and submit data confidentially through a secure web-based form. Respondents will then be able to compare their results with aggregate data from other demographically similar organizations. The assessment will be available on the websites of ISMP (www.ismp.org), ISMP Canada (www.ismp-canada.org), ISOPP (www.isopp.org), as well as other organizations that will help support its use. The development of the oncology medication safety self assessment is being supported through a grant from ISOPP to ISMP and ISMP Canada. The Clinical Excellence Commission and the Cancer Institute of New South Wales have also provided grant support and their expertise to this project. Private sector support was received from Baxter Corporation, ICU Medical, Inc., Pfizer Oncology, and Roche. We encourage you to complete the self assessment as soon as it is available to you. Please watch for announcements and encourage your colleagues to also complete this important evaluation.